Stock Track | Verona Pharma Soars 7.36% on Strong Ohtuvayre Sales and Positive Clinical Trial Progress

Stock Track

02-27

Shares of Verona Pharma plc (NASDAQ: VRNA) soared 7.36% in pre-market trading on Thursday, following the company's fourth quarter and full-year 2024 financial results that showed strong sales momentum for its newly launched COPD drug Ohtuvayre and progress in its Phase 2 clinical trials.

According to the financial report, net sales of Ohtuvayre reached $36.6 million in Q4 2024 and $42.3 million for the full year 2024, marking a successful launch for the company's first commercial product. Verona Pharma also initiated two Phase 2 trials in Q3 2024, evaluating nebulized ensifentrine in combination with glycopyrrolate for COPD and in patients with bronchiectasis.

The company plans to start a Phase 2b trial in the second half of 2025 to assess the safety and efficacy of a fixed-dose nebulized combination of ensifentrine and glycopyrrolate for COPD treatment. Additionally, Verona Pharma is progressing regulatory activities for potential marketing authorization applications for Ohtuvayre in the European Union and the UK.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1108141824"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1108141824\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1108141824?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-27 23:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108141824","market":"us","top_or_hot":-1,"title":"Stock Track | Verona Pharma Soars 7.36% on Strong Ohtuvayre Sales and Positive Clinical Trial Progress","media":"Stock Track","content":"<p>Shares of Verona Pharma plc (NASDAQ: VRNA) soared 7.36% in pre-market trading on Thursday, following the company's fourth quarter and full-year 2024 financial results that showed strong sales momentum for its newly launched COPD drug Ohtuvayre and progress in its Phase 2 clinical trials.</p>\n\n<p>According to the financial report, net sales of Ohtuvayre reached $36.6 million in Q4 2024 and $42.3 million for the full year 2024, marking a successful launch for the company's first commercial product. Verona Pharma also initiated two Phase 2 trials in Q3 2024, evaluating nebulized ensifentrine in combination with glycopyrrolate for COPD and in patients with bronchiectasis.</p>\n\n<p>The company plans to start a Phase 2b trial in the second half of 2025 to assess the safety and efficacy of a fixed-dose nebulized combination of ensifentrine and glycopyrrolate for COPD treatment. Additionally, Verona Pharma is progressing regulatory activities for potential marketing authorization applications for Ohtuvayre in the European Union and the UK.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Verona Pharma Soars 7.36% on Strong Ohtuvayre Sales and Positive Clinical Trial Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Verona Pharma Soars 7.36% on Strong Ohtuvayre Sales and Positive Clinical Trial Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-27 23:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Verona Pharma plc (NASDAQ: VRNA) soared 7.36% in pre-market trading on Thursday, following the company's fourth quarter and full-year 2024 financial results that showed strong sales momentum for its newly launched COPD drug Ohtuvayre and progress in its Phase 2 clinical trials.</p>\n\n<p>According to the financial report, net sales of Ohtuvayre reached $36.6 million in Q4 2024 and $42.3 million for the full year 2024, marking a successful launch for the company's first commercial product. Verona Pharma also initiated two Phase 2 trials in Q3 2024, evaluating nebulized ensifentrine in combination with glycopyrrolate for COPD and in patients with bronchiectasis.</p>\n\n<p>The company plans to start a Phase 2b trial in the second half of 2025 to assess the safety and efficacy of a fixed-dose nebulized combination of ensifentrine and glycopyrrolate for COPD treatment. Additionally, Verona Pharma is progressing regulatory activities for potential marketing authorization applications for Ohtuvayre in the European Union and the UK.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VRNA","symbol_name":"维罗纳制药","start_time":0,"source_url":"","article_id":"1108141824","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108141824","pubTimestamp":1740668925,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Verona Pharma plc  soared 7.36% in pre-market trading on Thursday, following the company's fourth quarter and full-year 2024 financial results that showed strong sales momentum for its newly launched COPD drug Ohtuvayre and progress in its Phase 2 clinical trials.According to the financial report, net sales of Ohtuvayre reached $36.6 million in Q4 2024 and $42.3 million for the full year 2024, marking a successful launch for the company's first commercial product. Verona Pharma also in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VRNA":"维罗纳制药"},"translate_title":"股票赛道Verona Pharma因Ohtuvayre销售强劲和临床试验进展积极而飙升7.36%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRNA":1},"content_text":"Shares of Verona Pharma plc (NASDAQ: VRNA) soared 7.36% in pre-market trading on Thursday, following the company's fourth quarter and full-year 2024 financial results that showed strong sales momentum for its newly launched COPD drug Ohtuvayre and progress in its Phase 2 clinical trials.\nAccording to the financial report, net sales of Ohtuvayre reached $36.6 million in Q4 2024 and $42.3 million for the full year 2024, marking a successful launch for the company's first commercial product. Verona Pharma also initiated two Phase 2 trials in Q3 2024, evaluating nebulized ensifentrine in combination with glycopyrrolate for COPD and in patients with bronchiectasis.\nThe company plans to start a Phase 2b trial in the second half of 2025 to assess the safety and efficacy of a fixed-dose nebulized combination of ensifentrine and glycopyrrolate for COPD treatment. Additionally, Verona Pharma is progressing regulatory activities for potential marketing authorization applications for Ohtuvayre in the European Union and the UK.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}